Beta-blockers in patients with uncomplicated arterial hypertension: data from the Campania Salute Network Registry

Clicks: 4
ID: 315003
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #42 of 71 articles by views in european heart journal - quality of care and clinical outcomes

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: The role of beta-blockers in the management of uncomplicated arterial hypertension remains a subject of clinical debate. While beta-blockers are established cornerstones for heart failure and post-myocardial infarction care, their independent efficacy in reducing major adverse cardiovascular events (MACE) in patients without these compelling indications is less clear. This study aimed to evaluate the association between beta-blocker use and MACE in a real-world hypertensive population without prevalent cardiovascular diseases. METHODS: We analyzed 6,702 hypertensive patients from the Campania Salute Network (CSN) registry without prevalent coronary or cerebrovascular disease, valvular heart disease, or heart failure. The association between beta-blocker use and MACE was assessed using three statistical approaches: multivariable-adjusted Cox proportional hazards regression, propensity score matching (PSM), and overlap weighting (OW). An intention-to-treat (ITT) analysis was performed based on baseline prescription, and an exploratory per-protocol (PP) sensitivity analysis was conducted to evaluate the role of sustained treatment adherence. RESULTS: At baseline, 18.1% (n=1,247) of patients were receiving a beta-blocker. Over a median follow-up of 52 months, 308 MACE (4.5%) occurred. After multivariable adjustment and weighting, beta-blocker use was not associated with a lower risk of MACE in the ITT population (Adjusted hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.86-1.52; PSM HR 1.18, 95% CI 0.82-1.70; OW HR 1.10, 95% CI 0.82-1.46). In the exploratory PP sensitivity analysis, even among adherent patients, beta-blocker therapy was not associated with a lower risk of MACE. Conversely, adherence to renin-angiotensin system inhibitors and statins was associated with a lower risk of MACE. Beta-blocker users also exhibited a higher prevalence of metabolic risk factors, including elevated triglycerides, glycemia, and uric acid levels. CONCLUSIONS: In patients with uncomplicated hypertension, beta-blocker use was not associated with a lower risk of MACE, regardless of treatment adherence. These findings are consistent with clinical guidelines that prioritize non-beta-blocker regimens and recommend using beta-blockers in the presence of compelling indications.
Reference Key
openalex_W7162414987 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Christian Basile, Costantino Mancusi, Ilaria Fucile, Valentina Trimarco, Eduardo Bossone, Maria Lembo, Grazia Canciello, Daniela Pacella, Giuseppe Giugliano, Maria Angela Losi, R Piccolo, Raffaele Izzo, Carmine Morisco, G Esposito
Journal european heart journal - quality of care and clinical outcomes
Year 2026
DOI
10.1093/ehjqcco/qcag089
URL
https://doi.org/10.1093/ehjqcco/qcag089
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.